Product Images Simvastatin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 4 images provide visual information about the product associated with Simvastatin NDC 70518-3349 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Remedy_Label - Remedy Label

Remedy_Label - Remedy Label

Simvastatin is a prescription-only medication that is produced by Lupin Ltd in India. It is recommended to keep this medication out of reach of children. The package insert should be referred to for directions of use. The medication should be stored at a temperature between 20-26°C with occasional excursions permitted up to 15-30°C. This specific package of Simvastatin has been repackaged by RemedyRepack Inc in Indiana.*

MM2 - Simvastatin 40mg 70518 3349 01

MM2 - Simvastatin 40mg 70518 3349 01

Simvastatin is a prescription drug manufactured by Lupin Ltd in India that is used to lower cholesterol levels. The medication comes in tablet form and needs to be stored at room temperature, with excursions permitted to certain temperatures. The package insert has directions for use, and patients should keep the drug out of the reach of children. The drug's expiration date and lot number are also listed, and it has been repackaged by RemedyRepack Inc.*

fig01 - ae7ee793 92ec 44e2 85d2 33a672edd54e 01

fig01 - ae7ee793 92ec 44e2 85d2 33a672edd54e 01

fig1 - ae7ee793 92ec 44e2 85d2 33a672edd54e 02

fig1 - ae7ee793 92ec 44e2 85d2 33a672edd54e 02

This text describes the results of a study on the effect of treatment with Simvastatin on major vascular events and major coronary events in HPS. The results are presented in a table format with the characteristics of the patients, such as age, gender, LDL, HDL-cholesterol, and incidence of events, along with the corresponding risk ratio. The study involved patients with and without CHD, diabetes mellitus, peripheral vascular disease, and cerebrovascular disease. The results show that Simvastatin treatment reduced the incidence of major vascular and coronary events in comparison to the placebo group across all patient characteristics except for those with diabetes mellitus, where the effects of the treatment were more limited.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.